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ABSTRACT: Evidence for a central role of amyloid β-protein (Aβ) in the genesis of Alzheimer’s disease (AD) has led to
advanced human trials of Aβ-lowering agents. The “amyloid hypothesis” of AD postulates deleterious eﬀects of small, soluble
forms of Aβ on synaptic form and function. Because selectively targeting synaptotoxic forms of soluble Aβ could be
therapeutically advantageous, it is important to understand the full range of soluble Aβ derivatives. We previously described a
Chinese hamster ovary (CHO) cell line (7PA2 cells) that stably expresses mutant human amyloid precursor protein (APP).
Here, we extend this work by purifying an sodium dodecyl sulfate (SDS)-stable, ∼8 kDa Aβ species from the 7PA2 medium.
Mass spectrometry conﬁrmed its identity as a noncovalently bonded Aβ40 homodimer that impaired hippocampal long-term
potentiation (LTP) in vivo. We further report the detection of Aβ-containing fragments of APP in the 7PA2 medium that extend
N-terminal from Asp1 of Aβ. These N-terminally extended Aβ-containing monomeric fragments are distinct from soluble Aβ oligomers
formed from Aβ1-40/42 monomers and are bioactive synaptotoxins secreted by 7PA2 cells. Importantly, decreasing β-secretase
processing of APP elevated these alternative synaptotoxic APP fragments. We conclude that certain synaptotoxic Aβ-containing species
can arise from APP processing events N-terminal to the classical β-secretase cleavage site.
R
apid progress in the mechanistic study of several human
neurodegenerative diseases has revealed a potentially
common mode of pathogenesis: that small, soluble oligomers
of misfolded proteins, rather than much larger, insoluble ﬁbrous
deposits, play the principal role in initiating and propagating
neuronal injury. Examples of this reinterpretation have emerged
from the study of α-synuclein in Parkinson’s disease, huntingtin
in Huntington’s disease, and amyloid β-protein (Aβ) in Alzheimer’s
disease (AD). Studies of the latter disorder have accrued the most
evidence for the pathogenic oligomer hypothesis of neuro-
degeneration. Soluble oligomers of Aβ ranging from dimers to
dodecamers and somewhat larger assemblies have been shown to
impair synaptic structure and function in both cell culture and
animal models (for example, refs 1−7).
Because therapeutic approaches to AD and other protein
misfolding disorders could beneﬁt from selectively targeting
soluble neurotoxic protein oligomers, it has become increasingly
important to identify the full range of pathogenic forms of the
respectiveproteins.In1995,wereportedtheﬁrstexampleofacell
culture model (7PA2 cells: Chinese hamster ovary (CHO) cells
stably expressing Val717Phe human amyloid protein precursor
(APP)) in which the secretion of 4 kDa Aβ monomers was
accompaniedbythesecretionof∼8.5−12.5kDaAβ-immunoreactive
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Terms of Usespecies that, by immunochemical analysis and radiosequencing, had
the properties of dimers and trimers of Aβ.
8 Subsequently, we and
others showed that the latter larger species (but not the monomers)
released by the 7PA2 cells could disrupt hippocampal long-term
potentiation (LTP),
2,4,9 decrease dendritic spine density,
6,10 inhibit
synaptic vesicle recycling,
11 facilitate hippocampal long-term
depression,
12 and impair the memory of a learned behavior in adult
rodents.
13−16
Despitethisevidencethatlow-nAβoligomersinthe7PA2cell
conditioned medium (CM) produce multiple neural eﬀects
analogous to some key features of AD, the precise molecular
identityoftheoligomershasnotbeenestablished.Thisisinlarge
part due to the technical diﬃculties in purifying the low
(subnanomolar) quantitiesofsolubleAβoligomers intheCMof
these cells and then successfully ionizing the hydrophobic
oligomers during mass spectrometry in order to identify their
exact masses. In the current work, we have used a range of
biochemical,immunochemical,andmassspectrometricmethods
to analyze the Aβ species produced in this highly useful and
rather widely used cell culture model. Two principal ﬁndings
have emerged: (1) that the ∼8 kDa species has a mass indicating
that it is a noncovalently bonded dimer of Aβ, as originally
hypothesized, and (2) that there are also Aβ-immunoreactive
species in the CM which represent Aβ monomers that bear
sequences which are N-terminally extended (NTE) beyond the
conventionalAβAsp1startsite.Wedesignatethesenovelspecies
as NTE-Aβ. We show that while both authentic noncovalent
dimersandtheNTE-Aβpeptidescanimpairsynapticplasticityin
the hippocampus, NTE-Aβ species are much more abundant
than Aβ dimers in the particular CHO cell line we employ.
Importantly, treatment of the cells with pharmacological
inhibitors of β-secretase caused increased processing of APP via
this alternative pathway, producing more synaptotoxic NTE-Aβ
peptides. Our ﬁndings extend the range of Aβ-containing APP
peptides that are capable of impairing synaptic function and suggest
thatsynaptotoxicitycanarisefromAPPprocessingeventsinaddition
to the classical β-a n dγ-secretase cleavages that produce Aβ.
■ EXPERIMENTAL PROCEDURES
Reagents.Unlessotherwisestated,allchemicalsandreagents
were purchased from Sigma (Sigma-Aldrich, St. Louis, MO)
andwereofthehighestpurityavailable.SyntheticAβ(1−40)was
synthesized and puriﬁed byDr. James I. Elliott at Yale University
and was >99% pure. The β-secretase inhibitors N-(1S,2R)-1-
benzyl-3-(cyclopropylamino)-2-hydroxypropyl)-5-(methyl-
(methylsulfonyl)amino-N′-((1R)-1-phenylethyl)isophthalamide
(Compound IV) and H-EVNstatineVAEF-NH2 (Compound III)
were from Calbiochem (Billerica, MA). The γ-secretase inhibitors
(2S)-2-{[(3,5-diﬂuorophenyl)acetyl]amino}-N-[(3S)-1-methyl-2-
oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]propanamide
(Compound E) and N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-
S-phenylglycine tert-butyl ester (DAPT) were gifts of Dr. Mike
Wolfe (Center for Neurologic Diseases).
7PA2 and Flp-In CHO Cell Lines Bearing Mutant
Human APP. Cell culture media, fetal bovine serum (FBS),
and media supplements were from Invitrogen. Naïve, un-
transfected CHO cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal bovine serum,
100 units/mL penicillin, 100 μg/mL streptomycin, and 2 mM
L-glutamine. CHO cells stably transfected with human APP751
bearing the V717F mutation (7PA2 cells) were grown in CHO
mediumplusG418(200μg/mL).IsogenicCHOcelllinesstably
expressing humanAPP695withthewildtypesequenceorbearing
one of the following coding changes (i) Lys595Asn, (ii)
Met596Leu, or (iii) Met596Val were generated using the Flp-
In (Invitrogen). Brieﬂy, naïve CHO cells were transfected with
the pFRT/lacZeo vector using lipofectamine 2000, and cells
stably expressing β-galactosidase selected in medium supple-
mented with zeocin (0.1 mg/mL) and a clonal cell line (referred
to as pCHO-) were isolated by limiting dilution. DNA encoding
APP695 was cloned into pcDNA5/FRT and PCR site-directed
mutagenesis used to introduce single base changes resulting in
desired mutations at APP595 or APP596. The pOG44 plasmid and
pcDNA5/FRT-APP vectors were cotransfected into the pCHO-
host cell line. Flp-In cells stably expressing human APP were
selected using hygromycin (0.5 mg/mL) and conﬁrmed to lack
β-galactosidase activity and to express human APP.
For conditioning, cells were allowed to reach 90−100%
conﬂuency, washed once with unsupplemented DMEM (5 mL),
andincubatedfor∼15hinDMEM(5mL).CMwascollectedand
spun at 200g and 4 °C for 10 min to remove cellular debris, the
upper 4.5 mL removed, and centrifuged a second time (3000g,
10 min, 4 °C) to pellet particulate debris. To inhibit proteolysis,
Ethylenediaminetetraacetic acid (EDTA) was added to achieve a
ﬁnalconcentrationof50mMandCMusedimmediatelyorstored
at −80 °C pending use. Storing CM at −80 °C does not alter the
proﬁle of 6E10-reactive material immunoprecipitated by either
AW8 or R1282.
Antibodies. The antibodies used in this study are listed in
Table 1.
Immunoprecipitation (IP) of Cell Medium. Samples were
ﬁrstincubatedwith30μLofa1:1mixtureofproteinAsepharose
Table 1. Anti-APP Monoclonal and Polyclonal Antibodies
a
name monoclonal/polyclonal epitope source/ref Wblot dil./conc. IP dil./conc.
8E5 monoclonal APP444-592 Elan
45 N/A 5 μg/mL
Rita polyclonal APP527-540 Selkoe laboratory
8 N/A 1:50
Pre-β polyclonal APP577-596 Selkoe laboratory
8 1:500 1:50
1G6 monoclonal APP573-576 Covance N/A 10 μg/mL
3D6 monoclonal Aβ1−5(Asp1) Elan 1 μg/mL 5 μg/mL
82E1 monoclonal Aβ1−5(Asp1) immunobiological laboratories N/A 10 μg/mL
6E10 monoclonal Aβ6−10 Signet
31 1 μg/mL 5 μg/mL
4G8 monoclonal Aβ17−24 Signet
46 1 μg/mL 5 μg/mL
2G3 monoclonal Aβ31−40 Elan
47 2 μg/mL 5 μg/mL
21F12 monoclonal Aβ33−42 Elan
47 2 μg/mL 5 μg/mL
R1282 polyclonal raised to Aβ1−40 Selkoe laboratory
48 N/A 1:100
AW8 polyclonal raised to Aβ1−42 Walsh laboratory
49 N/A 1:100
C8 polyclonal to residues APP676−695 Selkoe laboratory
48 1:1000 1:50
aAPP numbering is based on the 695 isoform. Dil. = dilution; conc. = concentration; and N/A = not applicable.
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Germany) for 6 h at 4 °C. Beads were sedimented by
centrifugation at 3500g for 10 min and the cleared supernatant
incubated with appropriate antibody (Table 1) plus 30 μLo f
PAS/PGA and rocked on a nutator for 12−14 h at 4 °C.
Antibody−antigen complexes were collected and pellets washed
as described previously.
17
Polyacrylamide Gel Electrophoresis (PAGE) and West-
ern Blotting. Immunoprecipitated (IP’d) proteins were
released from the antibody complex by heating at 100 °Ci n
2× sample buﬀer and then electrophoresed on either hand
poured 16% polyacrylamide tris-tricine gels or precast 4−12%
polyacrylamide NuPAGE bis-tris gels from Invitrogen.
18
Proteins were transferred onto nitrocellulose membranes at
400mAfor2handthenmicrowavedin200mLofPBSat800W
for 90 s ×2. Membranes were blocked for 1 h at room
temperature in TBST containing 5% (w/v) skim milk and then
incubated with antibody (Table 1) for 1 h at room temperature
or12hat4°C.Membraneswerewashed6timesfor10minwith
PBS containing 0.05% (v/v) Tween 20 (PBST) and then
incubatedwithgoatantimouseinfrared800antibodyorantirabbit
800 infrared antibody (Rockland, Gilbertville, PA) diluted in
PBST containing 0.01% (w/v) SDS. Immunoreactive bands were
visualized using a Li-COR Odyssey infrared imaging system
(Li-COR, Lincoln, NE).
Western Blot Analysis of Size-Exclusion Chromatog-
raphy (SEC) Isolated 7PA2 Fractions. Fourteen milliliter
aliquots of 7PA2 CM were concentrated ∼10-fold (1.4 mL)
using Centriprep Ultracel YM-3 ﬁlters (Millipore, Carrigtwohill,
Co. Cork, Ireland) and concentrates used immediately or
stored at 4 °C for ≤24 h prior to use. One milliliter of 10-fold
concentrated 7PA2 CM was chromatographed on a Superdex 75
10/300 GL (Amersham Biosciences AB, Uppsala, Sweden)
eluted in 50 mM ammonium acetate at pH 8.5 at a ﬂow-rate of
0.8mL/minusinganAKTApuriﬁer(GEHealthcareBiosciences
AB, Uppsala, Sweden). One milliliter fractions were collected,
lyophilized,thenresuspendedin20μLofsamplebuﬀerandused
for Western blotting.
Puriﬁcation of Aβ from 7PA2 CM. After considerable
experimentation, a 4-step puriﬁcation strategy was implemented
(Figures 2 and 3). The ﬁrst step involved the removal of soluble
APP (APPs) from 7PA2 CM using DE23 cellulose. This was
achieved by adding DE23 cellulose (0.5 mL settled volume in
DMEM) to 5 mL of 7PA2 CM and gently rocking for 30 min at
room temperature. The APP-depleted CM was separated from
the DE23 cellulose using a 0.2 μM stericup vacuum ﬁlter unit
(Millipore, Carrigtwohill, Co. Cork, Ireland). Thereafter, the
supernatant was incubated with a 60 μL suspension of either (1)
AW8 conjugated to PAS or (2) 2G3/21F12 conjugated to PGA
(Figure 2) and gently mixed for 12 h at 4 °C. Beads were
sedimented by centrifugation (3500g for 10 min at 4 °C) and
washed using STEN buﬀers.
17 Bound proteins were eluted by
resuspendingthebeadsin100mMNH4OH(200μL)andvortex
mixingfor2min.Thesupernatantwasthentransferredtoaclean
tube, snap frozen, and lyophilized. Samples were resuspended in
20 mM ammonium acetate at pH 8.5 (buﬀer A, 5 mL) and used
for ligand aﬃnity chromatography. Brieﬂy, 30 mg of methanol-
washed dry KLVFFAE-Ac-HN-(CH2)3-CPG beads (Senexis
Limited, Cambridge, UK) was added to the immunopuriﬁed
7PA2preparationandincubatedwithgentleagitationfor30min.
Beads were recovered by centrifugation (3000g, 5 min) and
washed with 5% acetonitrile in buﬀer A (5 mL × 3) and then
elutedusing20%acetonitrileinbuﬀerA(5mL).Thesamplewas
then lyophilized and immediately prior to SEC dissolved in
50 mM ammonium acetate at pH 8.5 (1 mL), and applied to a
Superdex 75 column and eluted as describe above. Half milliliter
fractions were collected, an aliquot taken for LTP experiments,
and the remainder lyophilized and used for Western blot and
silver stain analysis.
Silver Staining and In-Gel Digestion of Excised SDS−
Polyacrylamide Bands for Liquid Chromatography (LC)
MALDI-TOF. Electrophoresed proteins were detected using the
protocol of Shevchenko et al.
19 and bands of interest excised
using a clean razor blade. Excised bands were cut into ∼1m m
pieces and silver stain removed by incubating the pieces in
500 μL of a 1:1 mixture of Silverquest Silver Stain Kit destaining
reagents A and B (Invitrogen, Carlsbad, CA, USA) for 3 h. Gel
pieces were washed brieﬂy with distilled water (500 μL × 2) and
then 50 mM ammonium bicarbonate in 50% ACN (500 μL × 2)
for30min.Gelpieceswerecompletelydehydratedbyincubation
in 100% ACN (500 μL) for 20 min and samples reduced to
dryness in a vacuum centrifuge.
Fortrypsindigests,200ngofporcinetrypsin(20μL,Promega,
Madison, WI, USA) was used to rehydrate the gel pieces. The
suspension was incubated for 3 h at 37 °C, and the reaction was
stopped by the addition of 1% formic acid (10 μL). For LysC
digestions, 200 ng of endoproteinase LysC (20 μL) was used to
rehydrate the gel pieces. Digests were incubated overnight at
30 °C and the reaction stopped with 1% formic acid (10 μL).
Samples were then bath sonicated for 30 min and 15 μL injected
onto a 75 μm × 30 cm column (New Objective, Woburn, MA,
USA) packed with a Magic C18 AQ stationary phase (Michrom
Biosciences, Auburn, CA, USA) connected to a Michrom Magic
2002capillaryHPLC(MichromBiosciences,Auburn,CA,USA).
Samples were eluted using a linear gradient of 0.1% aqueous
formic acid to 50% acetonitrile containing 0.1% formic over
50 min. Peaks corresponding to tryptic peptides were subjected
to nanospray ionization and analyzed using a Quadrupole-Time
of Flightmass spectrometer (QStar, Thermo Electron Corp, San
Jose, CA, USA).
InVivoLTP.AdultmaleWistarratswereanesthetizedwithan
intraperitoneal injection of urethane (1.5 g/kg), and a cannula
was implanted in the lateral cerebral ventricle 1 mm lateral to the
midline and 4 mm below the surface of the dura mater. Single
pathway recordings of excitatory post-synaptic potentials
(EPSPs) were recorded from the stratum radiatum in the CA1
area of the dorsal hippocampus in response to stimulation of the
ipsilateralSchaﬀercollateral/commissuralpathway.
4EPSPswere
evoked at a frequency of 0.033 Hz. Test EPSPs were stimulated
to give 50% of the maximum amplitude. High frequency
stimulation (HFS) to induce LTP consisted of 10 trains of 20
stimuli with an intertrain interval of 2 s and an interstimulus
interval of 5 ms (200 Hz). During HFS, the stimulation intensity
was adjusted to produce an EPSP ≥75% of the maximum
amplitude. Intracerebroventricular (icv) injection of the sample
was made 10 min prior to HFS and solutions injected at ∼5 μL
per min (total volume 10 μL).
Two-Dimensional Gel Electrophoresis of 7PA2 CM SEC
IsolatedFractions.7PA2CMwasconcentrated∼10-foldusing
a Centriprep Ultracel YM-3 ﬁlter and then used for SEC as in
Figures 1B and 4A. Fractions 8, 9, and 10 were pooled to a give a
preparation rich in Aβ immunoreactive species of masses
between ∼14 and 4 kDa. This material was then lyophilized,
reconstituted in 125 μL of rehydration buﬀer (7 M urea, 2 M
thiourea, 2% (w/v) CHAPS, and 0.2% (v/v) Pharmalyte, 3−10)
(GE Healthcare) and electrofocused on immobilized pH gradient
Biochemistry Article
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complete,IPGstripswereincubatedwith6mLofSDS-equilibration
buﬀer (6 M urea, 50 mM Tris, 2% (w/v) SDS, 30% (v/v) glycerol,
and 0.01% (w/v) phenol red) in a 15 mL tube for 15 min and then
placed on top of a 4−12% bis-tris gel. The IPG gel was secured in
positionwithagarosedissolvedinrunningbuﬀersothattheIPGgel
could be in contact the stacking gel. Molecular weight markers were
loaded in a well next to the IPG strip. Gels were electrophoresed at
50 V for 10 min, and then the voltage was increased to 120 V for
2.5 h. The IPG strip was removed from the top of the gel and
proteins in the gel transferred onto nitrocellulose and Western
blotted using 6E10 as described above and in Table 1.
Western Blot and Cyanogen Bromide Cleavage
Analysis of SEC-Isolated 7PA2 Fractions. Concentrated
7PA2 CM was chromatographed on a Superdex 75 column and
fractions collected as described above. Then fractions 8 and 9
(designated as Oligo), and fraction 10 (designated as Mono)
were lyophilized in separate microcentrifuge tubes.Lyophilizates
weredissolvedin30μLof70%formicacid±0.1MCNBr.Tubes
were capped under nitrogen, vortexed, and then spun gently to
move solutions to the bottom of the tubes. Samples were
incubated in the dark at room temperature for 20 h, after which
330 μL of Milli-Q water was added and the contents frozen and
lyophilized. Dry samples were reconstituted in 2× sample buﬀer
sample,electrophoresedon12%polyacrylamidebis-trisgels,and
proteins transferred onto nitrocellulose and Western blotted as
described above.
In Vitro LTP. Brains from ∼6−8 week old C57BL/6x129
mice were quickly removed and submerged in ice-cold
oxygenated cutting solution.
12 Transverse slices (350 μm
thick) were cut with a vibroslicer from the middle portion of
each hippocampus. Slices were then incubated in artiﬁcial
cerebrospinal ﬂuid (ACSF), subsequently transferred to a
recording chamber, and continuously perfused at RT (∼24 °C)
with 9 mL of ACSF saturated with 95% O2 and 5% CO2. Field
EPSPs (fEPSP) were recorded in the CA1 region of hippo-
campus induced by test stimuli at 0.05 Hz with an intensity that
elicited an fEPSP amplitude of 40−50% of maximum. Once a
stable baseline was achieved, 1 mL of test medium was added to
the perfusion bath and the slice incubated for a further 20 min
prior to stimulation. Thereafter, LTP was induced by two
consecutive trains (1 s) of stimuli at 100 Hz.
■ RESULTS
MediumConditionedby7PA2CellsContainAβ-Immunor-
eactiveSpeciesWhichMigrateonSDS−PAGEandElutefrom
Size Exclusion with Molecular Weights Consistent with Aβ
Monomers, Dimers, and Trimers. 7PA2 cells stably express
human APP751 bearing the V717F familial AD mutation and
secrete signiﬁcant amounts of APP metabolites into their
Figure 1. 7PA2 conditioned medium contains Aβ-immunoreactive species which migrate on SDS−PAGE with molecular weights consistent for Aβ
monomer, dimers, and trimers. (A) Conditioned medium from 7PA2 and untransfected CHO cells (3 mL per lane) were IP’d with the pan anti-Aβ
polyclonal antibody, AW8, and then Western blotted using the antibodies indicated at the top of each panel. M, D, and T denote the position where
putativeAβmonomer,dimer,andtrimerspeciesmigrate.p3referstothewell-known∼3kDaproductofα-/γ-secretasecleavagethatisdetectedby2G3
and 21F12. (B and C) 1 mL of 10× concentrated 7PA2 CM was chromatographed on a Superdex 75 column, fractions collected, lyophilized, and used
for SDS−PAGE and Western blotting (B) or silver stain (C). The migrations of SDS−PAGE molecular weight standards (in kDa) are indicated on the
left, and elution of linear dextran SEC standards of 9.9 and 4.4 kDa are indicated by vertical arrows.
Biochemistry Article
dx.doi.org/10.1021/bi5003053 | Biochemistry 2014, 53, 3908−3921 3911medium.
2,8,21 Since the total amount of ELISA-detectable Aβ
secreted by these cells is in the low to subnanomolar range,
22
immunoprecipitation (IP) with polyclonal pan anti-Aβ antibod-
ies has been widely used to concentrate and facilitate the
detection of 7PA2 Aβ (reviewed in ref 18). Here, we show that
when7PA2CMisIP’dwithAW8andWesternblottedwithanti-
Aβ monoclonal antibodies, a ladder of bands between ∼3 and
∼16 kDa is detected (Figure 1A). Speciﬁcally, AW8 captures
∼4.5, 5.8, 8.5/9 (a doublet) and ∼12.5 kDa species that react
withN-terminal(6E10),midregion(4G8),andC-terminal(2G3
and 21F12) anti-Aβ antibodies (Figure 1A). It should be noted
that in these IP/Western blot experiments, nonspeciﬁc high
molecular weight bands are observed in the CM of both 7PA2
and CHO cells, most of which are due to the detection of the IP
antibody by the secondary antibody used for immunoblotting.
Importantly, when 7PA2 CM is subjected to native SEC, Aβ-
immunoreactive species elute with molecular weights consistent
with estimates made using denaturing SDS−PAGE (Figure 1B),
that is, with sizes indicative of Aβ monomer, dimers, and trimers.
Inprior studies, wefoundthattheplasticity-disrupting activity of
7PA2 CM was present in SEC fractions that contain the ∼8.5/9
and ∼12.5 kDa species.
4,9,13 However, silver staining of the same
SECfractions demonstrates that theproteins recognized byanti-
Aβ antibodies contribute only a small portion of the total proteins
present(Figure1C).Thus,inordertodeﬁnitivelyascribebioactivity
to the ∼8.5/9 and ∼12.5 kDa Aβ-reactive species, we sought to
purify these species to homogeneity, test their eﬀect on LTP, and
determine their primary sequence by mass spectrometry.
Puriﬁcation of an SDS-Stable Aβ Dimer from the 7PA2
Conditioned Medium. In order to identify methods suitable
for purifying Aβ species from 7PA2 CM, numerous chromatog-
raphies were tested for their ability to bind Aβ and remove
extraneous proteins, as assessed by IP/WB and qualitative silver
staining.Thechromatographiestestedincluded(1)hydrophobic
interaction,(2)diolnormalphase,(3)PCMcationexchange,(4)
C18 reverse-phase, (5) MonoQ anion-exchange, (6) DE23
anion-exchange, (7) immunoaﬃnity capture, and (8) ligand-
binding.Theﬁrstthreechomatographiesshowedlittleaﬃnityfor
Aβ and were not investigated further, and various combinations
of C18, anion-exchange, immunoaﬃnity, and ligand binding
were tested. After extensive testing, the four-step protocol
outlined in Figure 2A produced the best yield and highest purity
of Aβ species and comprised the (1) removal of large amounts
of soluble APP (APPs); (2) use of immunoaﬃnity methods
toenrichAβspecies;(3)useofapeptideligand(KLVFFAE)asa
homotypicAβaﬃnityreagent; (4)separation oftheresultantAβ
assemblies by size-exclusion chromatography; and then electro-
phoresis of the SEC fractions on SDS−PAGE. Step 2 used either
protein-A-sepharose-coupled AW8 antiserum (AW8-PAS)
(Figure 2) or protein-G-agarose-coupled 2G3/21F12 (2G3/
21F12-PGA), both of which yielded similar results (compare
Figure 2B and C to D and E). 6E10 Western blotting of material
puriﬁed as outlined in Figure 2A revealed that the ∼4.5 kDa
monomer and the ∼8.5 kDa dimer elute in SEC fractions 16−22
and 14−21, respectively, with peak levels of monomers and
dimers in fractions 20 and 17, respectively (Figure 2B). Silver
staining of these fractions showed peaks of total protein tracking
with immunoreactivity (Figure 2C). Similar results were
obtainedwhen2G3/21F12-PGAwasusedastheimmunoaﬃnity
reagent (Figure 2E). Compared to the greater amounts of Aβ
puriﬁedbyAW8-PAS,the∼4.5and∼8.5kDaspeciespuriﬁedby
2G3/21F12-PGA eluted in a smaller number of SEC fractions:
16−17 and 18−22 for the monomer and dimer, respectively.
Each puriﬁcation started with 50 mL of CM, and 30% of the
ﬁnal SEC fractions were used for the 6E10 immunoblot.
Comparison of starting material and puriﬁed material indicates
the excellent recovery of the monomer, reasonable recovery of
the dimer, and no recovery of the trimer.
Mass Spectrometry of Puriﬁed, Cell-Secreted Aβ
Indicates the Presence of SDS-Stable Dimers Composed of
TwoUnmodiﬁedAβ1−40Monomers.The∼4.5and∼8.5kDa
species puriﬁed from 7PA2 CM as described in Figure 2 were
excised from silver-stained polyacrylamide gels, digested with
proteases, and used for matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF
MS). Liquid chromatography-separated tryptic digests of the
∼4.5kDamonomerbandproducedpeakswithmassesconsistent
with the expected products of trypsin-cleaved Aβ1−40, that is,
Aβ1−5, Aβ6−16, Aβ17−28, and Aβ29−40 (with a methio-
nine35 sulfoxide) (Figure 3A,B; Table 2). These results are in
keeping with the fact that Aβ1−40 is the predominant Aβ
peptide secreted by 7PA2 cells and that peptides with other C-
termini are only present at low levels.
21,23 Importantly, tryptic
digests of the ∼8.5 kDa band also produced mass peaks
corresponding to Aβ fragments 1−5, 17−28, and 29−40
(methionine-sulfoxide) (Figure 3C; Table 2); however, Aβ6−
16 was not identiﬁed. Detection of the 6−16 fragment is crucial
to discriminate between noncovalently and covalently cross-
linked dimers. Under certain circumstances, Aβ can be induced
to form covalently linked dimers, either by phenolic coupling of
tyrosine10
24−26 or by formation of an intermolecular isopeptide
bondbetweenLys16andGln15.
27,28Inboththesetypesofcross-
linked dimers, tryptic digestion would not yield the 6−16
fragment released from the Aβ monomer but instead would give
risetomuchlargerfragments.ThefailuretodetectAβ6−16from
trypsin digests of the ∼8.5 kDa band (Figure 3C) could have
been due to diﬃculty recovering that fragment from HPLC or
due to a cross-link within it. To address both possibilities, we
employed an alternate digestion protocol. LysC selectively
cleaves the C-terminal to lysine residues and should generate the
longer 1−16 fragment of Aβ from a noncovalent dimer. When
the four-step puriﬁed, gel-extracted ∼8.5 kDa Aβ species is
analyzed in this way, the 1−16 fragment is observed, along with
the17−28andmethionine35-oxidized29−40fragments(Figure
3D; Table 2; and Figure S2, Supporting Information), thus
conﬁrming the identity of the puriﬁed ∼8.5 kDa band as a
noncovalently linked dimer of Aβ1−40. It is important to note
that the sortofMALDI-TOF MSused hereisnotquantitative; it
demonstrates the presence of dimers formed from Aβ1−40 but
does not provide information about their abundance.
Puriﬁed Aβ Dimer from 7PA2 Medium Inhibits LTP in
Vivo. To conﬁrm that the bona ﬁde Aβ dimers puriﬁed from
7PA2 medium (above) perturb synapse physiology, the puriﬁed
dimer was tested for its ability to inhibit LTP in vivo upon
intracerebroventricular microinjection in healthy adult rats.
This icv approach was taken because it requires only small
sample volumes (≤10 μL) and because we have previously
shown that injection of both whole 7PA2 CM and dimer-rich
SEC fractions thereof disrupt LTP.
2,4 High frequency
stimulation (HFS) of the hippocampal Schaﬀer collateral
pathway ﬁbers in rats that had received the vehicle resulted in
theexpectedinductionofLTPthatpersistedforthecourseofthe
experiment (145 ± 10% at 3 h post-HFS relative to baseline
EPSP amplitude) (Figure 3E, black). In contrast, when rats were
injected with the puriﬁed Aβ dimer (of estimated concentration
between 0.25 and 2.5 pM), a marked and statistically signiﬁcant
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at3hpost-HFS)(Figure3E,red).Theseresultsclearlydemonstrate
that a puriﬁed, cell-derived Aβ dimer conﬁrmed by mass spectro-
metry inhibits LTP in vivo at subnanomolar concentrations in the
absence of other factors.
7PA2 Cells Also Secrete Aβ-Immunoreactive Peptides
That Lack a Free Asp1 N-Terminus. The above puriﬁcation
and mass spectrometry indicate the presence of bona ﬁde Aβ
dimers in the 7PA2 medium. However, the fact that the putative
AβtrimerintheCMdoesnotcopurifywithmonomeranddimer
Figure 2. Multistep protocol for the puriﬁcation of cell-derived, soluble Aβ monomers and dimers. (A) The ﬂowchart illustrates the order of individual
chromatographic steps. Steps 1−3 were carried out sequentially in batch mode, beginning with 5 mL of 7PA2 CM. The products of 10 such 3-step
experiments were then pooled and used for the ﬁnal SECfractionation (step 4).Results for experiments usingAW8 for immunocapture are shown in B
and C, and those using 2G3/21F12 are shown in D and E. (B and D) Final SEC fractions were lyophilized and analyzed by Western blot using 6E10
(30% of each 0.5 mL fraction) and silver stain (60% of each 0.5 mL fraction). The ﬁrst lane in B and D is an AW8 IP of the starting (unmanipulated)
7PA2CM, whereas the ﬁrst lane inC and E isa direct loadof 20 μL of the sameCM. The indicated amounts of synthetic Aβ1−40 were loaded to allow
estimationoftheamountofAβrecoveredintheSECfractions.M,D,andTdenotethepositionwhereputativeAβmonomer,dimer,andtrimerspecies
migrate, and the migrations of molecular weight standards (in kDa) are indicated on the left.
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(Figure 2B and C) whereas a doublet of putative dimers is
apparentinunfractionated7PA2CM(Figure1A)suggestedthat
thepuriﬁed∼8.5kDadimer,andthe∼9.5and∼12.5kDaspecies
have distinct physical properties. Indeed, this supposition is
supported by immunochemical results using 3D6, a monoclonal
antibody that speciﬁcally recognizes the free Asp1 N-terminal
residue of Aβ generated by β-secretase.
29,30 Although 3D6
detects Aβ monomers in SEC fractions 10−11 oﬀ of our
Superdex 75column(whichcorrespond toaMWof∼4−5kDa)
and also faintly detects much larger Aβ-immunoreactive species
(>70 kDa) running natively in the void volume (fractions 5−6),
t h ei n t e r m e d i a t es o l u b l es p e c i e st h a tm i g r a t eh i g h e rt h a n∼4.5 kDa
on SDS−PAGE and occur in SEC fractions 7−9 as detected by
6E10 (Figure 4A, left panel and Figure S2, Supporting
Information) are not detectable by 3D6 (Figure 4A, right panels
and Figure S2, Supporting Information). The cause of the
apparent conﬂict between the mass spectrometry data on the
Figure 3. MS-conﬁrmed Aβ dimer from 7PA2 CM inhibits LTP in the hippocampus. (A) The single-letter amino acid code of Aβ1−40 peptide
fragments resulting from digestion using trypsin or LysC. (B−D) Puriﬁed 7PA2 CM-derived Aβ obtained using an AW8-PGA aﬃnity conjugate (see
Figure2),andbandscorrespondingtothe∼4.5kDamonomeror8.5/9kDadimerwereexcisedandsubjectedtoin-geldigestionusingtrypsin(B−C)or
lysC (D). Total ion chromatograms are depicted on the right. Peaks with masses corresponding to Aβ1−5, Aβ6−16, Aβ1−16, Aβ17−28, or Aβ29−40
areindicated byarrows. Metox. indicates a massmatch incorporating oxidizedmethionine 35. TheY-axis onthe ionchromatograms represent arbitrary
intensity expressed as counts per second (cps). The X-axis on the ion chromatograms represent the elution time (min) of components from the Magic
C18AQcolumn.MandDindicateAβmonomeranddimer,respectively.(E)SynapticﬁeldpotentialswererecordedfromtheCA1areaofanesthetized
male Wistar rats. Samples (10 μL) were injected i.c.v. (*) into healthy adult rats 10 min prior to the induction of LTP by a high-frequency stimulus
(HFS). Injection of puriﬁed Aβ dimer from 7PA2 CM signiﬁcantly inhibited LTP (red circles, 103 ± 3% at 3 h post-HFS, n =5 ,P < 0.05) compared to
that in the vehicle (black diamonds, 145 ± 10% at 3 post-HFS). Typical EPSPs at (1) ∼5 min pre-HFS and (2) ∼3 h post-HFS are shown on the right.
Statistical comparison of the data was performed on the last 10 min epoch prior to the 3 h time using an unpaired ANOVA. Calibration bars (right) are
10 ms/0.5 mV.
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dimer beginning at Asp1, and the inability to detect this ∼8 kDa
band with 3D6 on IP/WBs of the total CM is not yet clear. It is
possible that the puriﬁcation procedure facilitated the enrich-
ment of a low-abundance Asp1 dimer that otherwise is not
readily detected. In any event, our immunochemical results
indicate the presence in CM of low MW Aβ-immunoreactive
APP fragments that do not have an exposed (free) Asp1
N-terminus required for the binding of 3D6.
To further examine this possibility, we conducted a series of
sequential IP experiments using antibodies raised to various
human APP sequences within and ﬂanking the Aβ region.
Following each such IP, we then performed a second IP on the
residual supernatant using the pan anti-Aβ antiserum, R1282, in
order to observe any Aβ-reactive species not brought down by
the ﬁrst IP. All of these samples were Western blotted in parallel
with 6E10, an antibody directed to Aβ residues 6−10.
31
Antibodies 4G8 (midregion) and 2G3 (Aβ40) plus 21F12
(Aβ42)wereabletoIPboththeAβmonomerandthehigherMW
bands detectable by 6E10 (Figure 4B). As expected, an antibody
raised to the cytoplasmic tail of APP (C8) did not IP any species
detectable by 6E10 (Figure 4B). However, pre-β, an antiserum
raised to a synthetic peptide of the 20 residues immediately
N-terminal to the β-secretase cleavage site (residues 577−
596 based on APP695 numbering; −1t o−20 relative to Asp1 of
Aβ),
8,32 recognized several peptides larger than ∼4.5 kDa that
appeared to comigrate in part with proteins IP’d by R1282; the
pre-β antibody did not detect the monomer (Figure 4B). This
unexpected ﬁnding suggests that certain species >4.5 kDa
recognized by 6E10 are extended N-terminal to the Asp1 of Aβ,
consistent with their lack of reactivity with 3D6 (Figure 4A and
Figure S3, Supporting Information), which requires a free Asp1
for recognition.
29,30 Importantly, antibodies with similar
speciﬁcities to 3D6 and pre-β (Table 1) produced highly
comparable results. That is, 82E1 (which is speciﬁc for Asp1
of Aβ) precipitated only the monomer, and 1G6 (which
recognizes an APP sequence ∼20 residues N-terminal of Asp1)
precipitated peptides between ∼8 and 14 kDa but not the
monomer (Figure S3, Supporting Information).
Table 2. LC-MALDI-TOF Detected Fragments Produced by
Digestion of Aβ Species Puriﬁed from 7PA2 CM
a
sample peptide measured mass
theoretical
mass(1+)
∼4.5kDamonomerfraction17 1−5 637.3(1+), 319.2(2+) 636.7
6−16 1336.2(1+), 668.2(2+) 1336.4
17−28 663.3(2+) 1325.5
29−40 Metox 1101.6(1+) 1101.4
∼8.5/9 kDa dimer fraction 16 1−5 637.3(1+), 319.2(2+) 636.7
17−28 663.3(2+) 1325.5
29−40 Metox 1101.6(1+) 1101.4
∼8.5/9 kDa dimer fraction 17 1−16 489.7(4+), 652.3(3+)
977.9(2+) 1955.0
17−28 663.3(2+) 1325.5
29−40 Metox 551.3(2+), 1101.6(1+) 1101.4
aMetox = methionine sulfoxide, and (1+)/(2+)/(3+)/(4+) = charge state.
Figure4.Themajorityofthe∼8.5/9kDaand∼12.5kDaAβ-immunoreactivespeciesin7PA2CMcontainresiduesN-terminalofAsp1ofAβ.(A)One
milliliter of 10-fold concentrated 7PA2 CM was injected onto a Superdex 75 column and 1 mL fractions collected (#3−13), lyophilized, and equal
volumes Western blotted with 6E10 (left panel) or 3D6 (right panel). M, D, and T denote the position where the putative Aβ monomer, dimer, and
trimerspeciesmigrate,andthemigrationofPAGEMWstandards(kDa)areindicatedontheleft.ElutionofBluedextran(void)andlineardextranSEC
standards of 9.9 and 4.4 kDa are indicated by vertical arrows. (B) 7PA2 CM (2 mL) was ﬁrst IP’d with the antibody indicated above the lanes labeled 1,
and the resultant supernatant was then IP’d with R1282 (lane 2). The polyclonal antibody pre-β, which recognizes APP sequences between residues
577−596lying N-terminalofAβAsp1,precipitated largeamountsof6E10-immunoreactive speciesandeﬀectivelydepletedCMofthe∼8.5/9 kDaand
∼12.5 kDa species otherwise precipitated by R1282. In contrast, the Asp1-speciﬁc antibody, 3D6, precipitated only an ∼4.5 kDa Aβ monomer leaving
most of the putative dimers and trimers to be precipitated by R1282.
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Bromide Cleavage Analysis Indicate That the Majority of
the Aβ-Immunoreactive ∼8.5/9 kDa and ∼12.5 kDa
Species in 7PA2 CM Have Extended N-Termini. Because
our original radiosequencing of the 7PA2 Aβ oligomers had
shownthatboththemonomerandtheputativedimerandtrimer
bands cut out of one-dimensional gels contained Aβ sequences
beginning at Asp1,
8 and because the current mass spectrometry
of the puriﬁed ∼8 kDa dimer band also indicated an Asp1 start
site (Figure 3), we used orthogonal biochemical methods to
determine whether 7PA2 cells actually secrete a mixture of
Aβ-containing species, some that begin at Asp1 and some with
N-termini extending “to the left” of Asp1. First, we preformed
two-dimensional gel electrophoresis (2DGE) employing iso-
electric focusing over a pH range capable of resolving authentic
Asp1-initiated Aβ species from N-terminally extended (NTE)
Aβ species. To produce a peptide preparation that could be
readily solubilized for isoelectric focusing, 7PA2 CM was
concentrated, depleted of APPs using DEAE sepharose, and then
chromatographed on a Superdex 75 column eluted in a volatile
buﬀer. Fractions 8, 9, and 10 were pooled and then lyophilized to a
give a preparation rich in Aβ-immunoreactive species of masses
between ∼14 and ∼4 kDa. This material was then subjected to
2DGE, i.e., isoelectric focusing in the horizontal dimension and
denaturing PAGE in the vertical dimension. Once separated in
this way, the proteins were transferred onto nitrocellulose, and
Aβ-immunoreactive bands were visualized using 6E10. Unexpect-
edly, only one 6E10-positive spot had an isoelectric point (pI) of
∼5.5 close to that expected for Aβ beginning at Asp1, and this
migrated in the lithium dodecyl sulfate (LDS)−PAGE dimension
at a molecular weight consistent with that of the Aβ monomer
(Figure 5A). All of the 6E10-positive bands that migrated on
LDS−PAGE with predicted masses ≥6 kDa have pIs less than
or equal to 5. Since Aβ peptides beginning at Asp1 and extend-
ing to Lys28 and beyond have predicted pIs of ∼5.3, and
noncovalent oligomers of Aβ1−40 monomers should have the
same pI as the monomer, the lack of species larger than the
monomerat∼pH5.3onour2Dgelsindicatedthattrueoligomers
are not detected by this method. The fact that the ∼8−9k D a
and 12−14 kDa species have pIs ≤5.0 is consistent with these
species having NTEs predicted to be ≥34 residues long (ExPASy
Proteomics server).
To complement this 2DGE approach, we used cleavage with
cyanogen bromide (CNBr) as another means to discriminate
between NTE-Aβand canonical Asp1-starting Aβ species. CNBr
cleaves polypeptides on the C-terminal side of methionines. Aβ
contains a single Met atposition 35, and in the 100 APP residues
N-terminal to the Aβ region, there are only 3 Met residues.
Fortuitously,oneoftheseisimmediatelyN-terminalofAsp1,and
therefore, CNBr cleavage of NTE-Aβ species should liberate Aβ
sequences beginning at Asp1. For these experiments, we
fractionated 7PA2 CM using SEC and studied the eﬀects of
CNBron the∼4.5kDa monomer fraction (Frac. 10) vsthe∼8−
12.5 kDa species (a pool of Frac. 8 and 9) (fraction numbering is
as in Figures 1B and 4A). Consistent with our prior results
(Figure4),theSEC-isolatedmonomer(“Mono−”inFigure5B)
migrates on SDS−PAGE as a single band at ∼4.5 kDa before
CNBrcleavageandisrecognizedby3D6(indicatingitsfreeAsp1
N-terminus), 6E10, and a combination of 2G3 + 21F12 (indicating
its free C-termini) but is not recognized by pre-β. Incubation of this
material with CNBr (“Mono +” lane in Figure 5B) results in loss of
reactivitywith2G3/21F12andaslightlyfastermigrationoftheband
detected by 3D6 and 6E10 (Figure 5B). This result is entirely
consistent with an Aβ species beginning at Asp1 and extending
C-terminal to at least Val40 that loses its C-terminal (2G3/21F12)
immunoreactivity after the cleavage by CNBr at Met35 of Aβ.I n
contrast, the same experiments on the ∼8−12.5 kDa species
indicatedthatthesespeciesareN-terminallyextendedbeyondAsp1.
For example, SEC fractions 8 and 9 contain little 3D6-reactive
species before CNBr (“Oligo −” in Figure 5B), but after CNBr
(“Oligo +”) treatment, a new and prominent 3D6-immunoreactive
∼4 kDa band has been generated. Similarly, CNBr treatment
markedly alters the species detectable by 6E10, i.e., it drastically
reduced the amount of ∼6−18 kDa species and produced a new
∼4kDaband.TheseCNBrcleavageexperiments,together withour
2DGE (Figure 5A) and immunoproﬁling (Figure 4B), clearly de-
monstrate that the majority of ∼8.5−12.5 kDa Aβ-immunoreactive
Figure 5. Two-dimensional gel electrophoresis and cyanogen bromide
cleavage analysis indicate that the majority of the Aβ-immunoreactive
∼8.5/9 kDa and ∼12.5 kDa species in 7PA2 CM have N-termini that
extend beyond Asp1. (A) One milliliter of 10-fold concentrated 7PA2
CM was used for SEC, and fractions rich in Aβ-immunoreactive species
of masses between ∼14 and ∼4 kDa (see Figure 4B) were pooled and
used for 2-dimensional gel electrophoresis with immobilized pH 4−7
gradient strips and 4−12% bis-tris gels. 6E10 was used for Western
blotting.MWmarkerswereloadedinthewellnexttothestrip,andtheir
migration is indicated on the left; the pH gradient is shown on the
bottom. The ∼4.5 kDa species migrated with the anticipated pI of Aβ
(i.e., ∼5.5), whereas the ∼8.5/9 kDa and ∼12.5 kDa species had lower
pI’s not compatible with oligomers of Aβ. (B) Ten-fold concentrated
7PA2 CM was fractionated using a Superdex 75 SEC column as
described above. Fractions 8−9 were pooled, lyophilized, and
designated as the putative oligomer (Oligo) fraction. Monomer-
containing fraction 10 (Mono) was lyophilized in a separate tube. The
Oligo and Mono samples were incubated overnight in 70% formic acid
± 0.1 M cyanogen bromide (CNBr). Thereafter, samples were
electrophoresed on a 12% bis-tris gel and Western blotted. For these
experiments, we used a sequential immunoblotting approach: ﬁrst using
pre-β (1st panel) and 2G3/21F12 (4th panel), and then reprobing the
pre-β blot with 6E10 (3rd panel) and the 2G3/21F12 blot with 3D6
(2nd panel). CNBr treatment (+) causes a slight down-shift in the
migrationofthemonomerdetectedby3D6and6E10andalossof2G3/
21F12 reactivity, results consistent with cleavage of the monomer after
Met35. CNBr treatment of the Oligo fraction (+) leads to the
appearance of an ∼4 kDa band recognized by 3D6, thus demonstrating
that the Oligo fraction contains N-terminally extended Aβ species.
Biochemistry Article
dx.doi.org/10.1021/bi5003053 | Biochemistry 2014, 53, 3908−3921 3916species in the 7PA2 CM are NTE-Aβ species and not oligomers of
Aβ monomers beginning at Asp1.
β-SecretaseInhibitionIncreasestheLevelsofN-Terminally
Extended Aβ-Containing Peptides in the 7PA2 CM. To
examine the nature of the proteolytic processing of APP that
could generate NTE-Aβ species, 7PA2 cells were conditioned in
the presence of β-o rγ-secretase inhibitors. In cells treated with
DAPT (a well-characterized γ-secretase inhibitor
33,34) all of the
bands in the lower gel region normally detected by 6E10,
including theAβ monomer, were decreased or not present in the
CM, conﬁrming that all of these Aβ-containing species are
dependent on γ-secretase processing, as expected (Figure 6A).
Compound IV, a β-secretase inhibitor,
35 decreased the generation
of the ∼4.5 kDa Aβ monomer, as expected, but signiﬁcantly
increasedthelevelsofthe6E10(Figure6A)andpre-β(Figure6B)
reactivespecies(migratingfrom∼5to∼15kDa),whencompared
to vehicle-treated (DMSO) cells. Importantly, a similar increase
was evident when other potent BACE-speciﬁc inhibitors such as
Compound III
36 (Figure S4, Supporting Information), Dr9,
37 or
Merck compound 3
35 (not shown) were used. These inhibitor
eﬀectsareconsistentwithotherrecentstudieson7PA2CM
21and
demonstrate that some 6E10-positive species migrating above the
monomer are generated by alternative proteolytic processing of
APP that increases when β-secretase-mediated production of the
monomer is pharmacologically inhibited.
To examine further the apparent lack of involvement of
β-secretase in generating certain 6E10-reactive APP fragments
migrating above the ∼4.5 kDa monomer, we stably transfected
parental CHO cells with APP constructs bearing single amino
acid substitutions within the β-secretase cleavage region. The
Flp-Intransfectionsystemwasusedtoensureequalexpressionof
each APP construct. Lys595Asn and Met596Leu missense
mutations in APP occur together in a Swedish kindred with
earlyonsetAD,
38andthismutantprecursorundergoesenhanced
cleavage by β-secretase to generate more Aβ monomers than
wild type (wt) APP does.
39−41 Consistent with the above BACE
inhibitor ﬁndings, these Swedish mutations preserve Aβ
monomer generation but decrease the amounts of 6E10-reactive
species >4.5 kDa (Figure 6C). Conversely, expression of an
artiﬁcialMet596Valmutationthatwepreviouslyfoundtosharply
decrease β-secretase cleavage of APP
42 lowers the production of
the Aβ monomer, as expected, but substantially increases the
generation of larger Aβ-immunoreactive species (Figure 6C).
These reciprocal ﬁndings, coupled with the BACE inhibitor
results (Figure 6A and B), indicate that the majority of the
Aβ-immunoreactive species detected by 6E10 above ∼4.5 kDa
do not arise from β-secretase processing, explaining their lack of
reactivity with 3D6 (Asp1-speciﬁc).
Theﬁndingswiththetwoβ-secretaseinhibitorsusedinFigure
6 and Figure S4 (Supporting Information) were conﬁrmed by a
pre-β IP of the CM from similarly treated 7PA2 cells: BACE
inhibitionincreasedthesecretionofspeciesprecipitablebypre-β,
whereas DAPT decreased most of these species (Figure 6B). Of
note, certain species IP’d by pre-β that migrate between ∼8 and
14 kDa and are detected by 6E10 are not altered by γ-secretase
inhibition,suggestingthataportionofthebandsdetectedbypre-
β represent a separate class of APP fragments generated by non-
γ-secretase events. Overall, our ﬁndings suggest the existence in
this cell line of APP cleavage event(s) occurring N-terminal to
thecanonical β-secretase site, followed byγ-secretase cleavage to
generate a C-terminus.
Secreted NTE-Aβ Species Inhibit Hippocampal LTP. In
view of our observation that soluble NTE-Aβ species constitute
the majority of Aβ-immunoreactive species larger than the Aβ
monomer in the 7PA2 CM, we asked whether the NTE-Aβ
species were also capable of impairing synaptic plasticity. To this
end,weperformedimmunodepletionsofeithertheAβoligomers
or the NTE-Aβ species from 7PA2 CM, in order to selectively
remove Aβ species having either a free Asp1 N-terminus or the
N-terminal extensions, respectively. Because the abundant amount
of APPsα present in 7PA2 CM could compete with the ability of
certain antisera to fully immunodeplete the Aβ-NTE species, 7PA2
CMwasﬁrstincubatedwithDE23anion-exchangecellulosetobind
andremovethehighlychargedAPPswhileleavingthevarious4−17
kDaAβ-immunoreactiveproductsinsolution.ThisAPPpreclearing
step generated CM that could then be quantitatively immunode-
pleted of the NTE species with the pre-β antiserum. C8, an
antiserum directed to the APP C-terminus, served as a negative
control since it did not immunodeplete any of the Aβ-containing
species found in 7PA2 CM (Figure 4B).
Incubation of 7PA2 CM with PAS and PAG beads in
the absence of antibody does not alter the detection of the
Figure 6. β-Secretase is not necessary for the generation of certain
higher MW Aβ-immunoreactive species. (A and B) Duplicate dishes of
7PA2cellswere conditioned for∼15hinthepresenceorabsenceof the
γ-secretaseinhibitor,DAPT(10μM);DMSOvehicle;ortheβ-secretase
inhibitor,compoundIV(3μM).CHO-istheCMofparentalCHOcells
notexpressinghumanAPP.CMwascollectedfromcellsandusedforIP
with (A) AW8 and (B) pre-β, and both Western blotted with 6E10.
DAPT treatment of 7PA2 cells blocks the secretion of most species
detectable by both R1282 IP and pre-β IP. Aβ monomer is signiﬁcantly
reduced in the presence of compound IV (C−IV), but 6E10
immunoreactive species migrating between ∼5−16 kDa are increased
in quantity. Importantly, certain species IP’d by pre-β are still produced
in the presence of DAPT, suggesting that these are not products of γ-
secretase activity. (C) Introducing the “Swedish” APP missense
mutations (K595N and M596L) increases Aβ monomer levels but
decreases levels of the ∼5−12.5 kDa 6E10-reactive species relative to
CHO cells expressing wtAPP. Conversely, an M596V mutation, which
reduces β-secretase cleavage, decreases Aβ monomers and increases the
higher MW species. M, D, and T denote the position where putative Aβ
monomer, dimer, and trimer species would migrate, and the migration
of MW standards (in kDa) are indicated on the left.
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consistent with previous observations,
2,9 this negative-control
“bead-treated”CMstillsigniﬁcantlyreducedLTPinadultmouse
hippocampus (116.9 ± 3.5% at 60 min, n = 10 slices) compared
to that by ACSF supplemented with bead-treated DMEM alone
(142.5 ± 3.4%, n = 11 slices; p < 0.01) (Figure 7A). Also in
accord with our prior work, 7PA2 CM immunodepleted with
R1282 no longer impaired LTP (132.4 ± 3.5%, n = 11; p < 0.01)
compared to that with CM treated with beads alone or
immunodepleted with antiserum C8 (117.4 ± 2.8%, n =8 )
(Figure 7B,D). Two rounds of immunodepletion of 7PA2 CM
withR1282essentiallyremovedallAβpeptidecontainingspecies
between ∼4 and 17 kDa (Figure 7D). Immunodepletion of the
CM with 3D6 did not signiﬁcantly rescue LTP (122.4 ± 3.8%,
n =1 0p > 0.05 for 3D6 compared to beads alone), whereas
immunodepletion with pre-β did (141.4 ± 3.2%, n =9 ;p < 0.01
compared to beads alone) (Figure 7C,D). The latter result
indicates that the N-terminally extended APP fragments
containing the intact Aβregion can impairhippocampal synaptic
plasticity, independent of any eﬀects of Aβ oligomers in the CM.
■ DISCUSSION
Cultured cells that express mutant human APP and secrete Aβ
peptides into their medium have been used to advantage in
numerous studies investigating thebiological eﬀects ofAβ. 7PA2
cells provided the ﬁrst example of a cell line that secreted
Aβ-immunoreactive species with biological activity.
2,8 These
species migrated on one-dimensional SDS−PAGE gels with
molecular weights expected for dimers and trimers were not
precipitable with antibodies to ﬂanking APP sequences and
showed radiosequencing patterns consistent with Aβ species
beginning at Asp1.
8 However, the precise chemical identity of
the Aβ-immunoreactive species secreted by these cells has not
been established heretofore. Consequently, we sought to purify
7PA2-derived ∼8.5−12.5 kDa Aβ-immunoreactive species to
homogeneity (as judged by silver staining), so as to determine
theirprimarysequence(bymassspectrometry)andsynaptotoxic
potential (by LTP assays).
Using a combination of anion-exchange, immuno-aﬃnity,
ligand-aﬃnity, and size-exclusion chromatographies, we success-
fully puriﬁed the ∼4.5 and ∼8 kDa Aβ species and deﬁnitively
identiﬁed them as monomer and noncovalent dimer, respec-
tively, of Aβ1−40. Thereafter, we demonstrated that the puriﬁed
Aβdimerfrom7PA2CM,freeofotherproteins,wassuﬃcientto
inhibit LTP in live wt rats. Why the ∼12.5 and 9 kDa 6E10-
reactive species were not recovered in the puriﬁcation procedure
used to isolate monomer and dimer is unclear. Nonetheless, the
preferential loss of these species during puriﬁcation suggests that
theyhavediﬀerentphysicalpropertiesthanthemonomerand∼8
kDa dimer. Indeed, in preliminary ion-exchange and reverse-
phase experiments (not shown), the ∼12.5 and 9 kDa species
eluted in a fashion that indicated that they are more negatively
charged than monomer and dimer and could therefore have
distinct primary sequences.
Figure 7. N-Terminally extended Aβ-containing species in 7PA2 CM inhibit hippocampal LTP. (A) Adult mouse hippocampus slices were exposed to
plain DMEM (black) or 7PA2 CM that had been mock-immunodepeleted with antibody-free beads (gray). (B) Immunodepletion with R1282 (blue)
signiﬁcantly decreases the impairment of LTP by 7PA2 CM, whereas immunodepletion with C8 (red) has no eﬀect. The shaded gray horizontal bar
representsthemean±2SEMofthetraceswith7PA2CMmock-treatedwithbeadsshowninA.(C)ImmunodepletionofNTEspecieswithpre-β(blue)
prevents the 7PA2 CM-mediated LTP impairment, but selective removal of only Aβ species starting with a free Asp1 (by antibody 3D6; red) does not
signiﬁcantly decrease the LTP impairment. (D) Western blots of samples IP’d with R1282, pre-β, and 3D6. Lanes 1 contain precipitates after a ﬁrst
round of IP with the indicated antibody; and lanes 2 contain precipitates after a second round of IP with the same antibody. The supernatant from this
second IP was used for LTP analysis in B and C. Lanes labeled 3 are the same supernatants used in B and C that were subsequently IP’d with R1282.
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7PA2 CM for the ﬁrst time an antibody (3D6) uniquely speciﬁc
for Asp1 of Aβ.
29,30 We observed APP fragments that could be
precipitated by pan anti-Aβ antisera (R1282; AW8) and blotted
by anti-Aβ monoclonal antibodies that are not Asp1 speciﬁc
(e.g., 6E10; 4G8) but that could not be detected using 3D6.
This unexpected ﬁnding led to the experiments herein that
demonstratedthatNTE-Aβspeciesaremajorcontributorstothe
plasticity-disrupting activity of 7PA2 CM. Speciﬁcally, certain
∼8−12.5 kDa Aβ-immunoreactive species are recognized by
antibodies (pre-β and 1G6) directed to a 20-residue region just
N-terminal to the β-secretase cleavage site, and these species
migrate on 2D-gels with sizes and pIs consistent with Aβ species
with N-terminal extensions >34 residues. Furthermore, treat-
ment of these species with CNBr leads to liberation of the Aβ
monomer beginning at Asp1. Most importantly, we present
compelling evidence that 7PA2-derived NTE-Aβ fragments
impair hippocampal LTP at subnanomolar concentrations and
that this synaptotoxic activity is speciﬁcally removed by selec-
tively immunodepleting them with the pre-β antiserum.
In view of these new ﬁndings, we re-examined our original
autoradiograms of IPs that had used pre-β vs anti-Aβ antibodies
8
and conﬁrmed that aliquots of CM of the 7PA2 cell line used at
that time (but no longer available) had distinct Aβ-reactive
species and pre-β-reactive species whose electrophoretic
migration did not overlap on gels or by sequential IPs with the
respective antibodies. The most parsimonious explanation for
the heterogeneity of Aβ-containing APP fragments that we
observe in the present study vs that in 1995 is that the level of
β-secretase activity in these non-neural cells changed with cell
passage over time. We hypothesize that more recent aliquots of
passaged 7PA2 cells have decreased β-secretase levels and/or
activity, allowing more APP holoproteins to be processed by
alternative proteases which are not inhibited by β-secretase
inhibitors and which cleave N-terminal to that Met-Asp site.
Taken together, our previous analyses
8 and those in the
current study indicate that 7PA2 cells generate signiﬁcant
amounts of Aβ monomers and NTE-Aβ species (which are also
monomeric) as well as small amounts of noncovalent Aβ1−40
dimers. In addition, we also found trace amounts high molecular
weight aggregates composed of monomer that eluted in the void
volume of a Superdex 75 column. Future studies will be required
to determine the relative synaptic potency of the dimers vs the
NTE-Aβ’s in the 7PA2 CM, but our experiments herein testing
the activity of 7PA2 CM immunodepleted with diﬀerent
antibodies indicate that NTE-Aβ’s are the primary plasticity-
disrupting activity in the current 7PA2 line. Moreover, we
present clear pharmacological evidence that the inhibition of
BACE leads to an increase in NTE-Aβ’s. These ﬁndings are
consistent with prior studies that tested BACE inhibitors on
7PA2 cells
21 and indicate that at least in CHO cells, APP can be
cleaved at sites N-terminal to Asp1 of the Aβ domain by one or
more proteases, the action of which are in competition with
BACE. Although these alternate species are monomeric APP
fragments, they apparently contain a conformation of the Aβ
region that confers synaptotoxic eﬀects, as measured by LTP
(Figure 7). Comparative studies using soluble Aβ oligomers
isolatedfromthehuman(AD)cortexorpure,syntheticAβshow
that the electrophysiological eﬀects of these NTE-Aβ monomers
are indistinguishable from those of the 7PA2 CM,
12,43 and all 3
sources can also induce AD-type τ hyperphosphorylation and
neuritic dystrophy in cultured primary rodent neurons.
43
We conclude that the heterogeneity of bioactive Aβ-containing
speciessecretedbythe7PA2celllinemakesthemausefulsource
ofsynaptotoxicAβ-positiveAPPfragments,includingAβdimers,
but suggests that any functional eﬀects should be compared to
those elicited by human brain-derived or synthetic Aβ dimers.
Indeed, given that our previous eﬀorts did not identify Aβ
oligomers or NTE-Aβ’s in the CM of human neuroblastoma cell
lines or primary cortical neurons,
17 it is seems likely that under
normal circumstances, neurons do not secrete signiﬁcant
amounts of Aβ oligomers or NTE-Aβ. Nevertheless, there is
evidence of alternate NTE-like Aβ-immunoreactive species in
human CSF.
44 Consequently, it will be important in future
studies to probe other cell culture systems and brain tissues for
such NTE-Aβ species, especially to learn whether (as observed
here)β-secretaseinhibitionleadstoariseinthelevelsofsynaptic
plasticity-disrupting NTE-Aβ’s. The latter phenomenon, if
conﬁrmed to occur in vivo, would have important implications
for the chronic inhibition of BACE1 in humans.
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Aβ, amyloid β-protein; ACN, acetonitrile; ACSF, artiﬁcial
cerebrospinal ﬂuid; AD, Alzheimer’s disease; BACE, β-amyloid
cleaving enzyme-1; Buﬀer A, 20 mM ammonium acetate at
pH 8.5; CHO, Chinese hamster ovary cells; CM, conditioned
medium; 2DGE, two-dimensional gel electrophoresis; DMEM,
Dulbecco’s modiﬁed Eagle’s medium; EDTA, Ethylenediamine-
tetraacetic acid; EPSP, excitatory postsynaptic potential; fEPSP,
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MALDI-TOF MS, matrix-assisted laser desorption/ionization-
time-of-ﬂight mass spectrometry; NTE, N-terminal extension;
7PA2, Chinese hamster ovary cells stably expressing human
APP751 bearing the V717F mutation; PAGE, polyacrylamide gel
electrophoresis; PAS, protein A sepharose; PGA, protein G
agarose; PBS, phosphate buﬀered saline; PBST, phosphate
buﬀered saline plus 0.05% (v/v) Tween 20; PCR, polymerase
chain reaction; pI, isoelectric point; RT, room temperature; S/
LDS−PAGE, sodium/lithium dodecyl sulfate−polyacrylamide
gelelectrophoresis;SEC,size-exclusionchromatography;STEN,
50 mM Tris at pH 7.4 containing 2 mM EDTA, 0.2% NP40, and
650 mM NaCl; TBS, tris-buﬀered saline; TBST, tris-buﬀered
saline plus 0.05% (v/v) Tween 20
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